Science Strategic Acquisition Alpha (Science Strategic Acquisition Alpha) Cash And Cash Equivalents : $0.45 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Science Strategic Acquisition Alpha Cash And Cash Equivalents?

Science Strategic Acquisition Alpha's quarterly cash and cash equivalents increased from Mar. 2022 ($0.35 Mil) to Jun. 2022 ($0.51 Mil) but then stayed the same from Jun. 2022 ($0.51 Mil) to Sep. 2022 ($0.45 Mil).

Science Strategic Acquisition Alpha's annual cash and cash equivalents increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.02 Mil) and increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.35 Mil).

Science Strategic Acquisition Alpha Cash And Cash Equivalents Historical Data

The historical data trend for Science Strategic Acquisition Alpha's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science Strategic Acquisition Alpha Cash And Cash Equivalents Chart

Science Strategic Acquisition Alpha Annual Data

Trend

Dec20

Dec21

Cash And Cash Equivalents

0.02

0.35

Science Strategic Acquisition Alpha Quarterly Data
	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial			0.74	0.35	0.35	0.51	0.45

Science Strategic Acquisition Alpha Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Science Strategic Acquisition Alpha (NAS:SSAAU) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Science Strategic Acquisition Alpha Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Science Strategic Acquisition Alpha's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Science Strategic Acquisition Alpha (Science Strategic Acquisition Alpha) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Science Strategic Acquisition Corp Alpha (NAS:SSAAU) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1447 2nd Street, Suite 200, Santa Monica, CA, USA, 90401

Website

https://www.science-inc.com

Science Strategic Acquisition Corp Alpha is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Executives

Michael Gwynne Jones	director, officer: CEO	24460 MALIBU ROAD, MALIBU CA 90265
Jeff Kearl	director	C/O SKULLCANDY, INC., 1441 WEST UTE BLVD., SUITE 250, PARK CITY UT 84908
April Henry	officer: EVP, Corporate Development	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401
Jennifer Rubio	director	C/O TISHMAN SPEYER PROPERTIES, L.P., ROCKEFELLER CENTER, 45 ROCKEFELLER PLAZA, NEW YORK NY 10111
Taylor Colette K.	director	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401
Greg Gilman	director	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401
Priscilla Guevara	officer: Global Head of IR	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401
Tom Dare	officer: CFO	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401
Peter Pham	officer: President	C/O SCIENCE STRATEGIC ACQUISITION CORP., 1447 2ND STREET, SANTA MONICA CA 90401

Science Strategic Acquisition Alpha (Science Strategic Acquisition Alpha) Headlines

No Headlines